Becton, Dickinson and Company (NYSE:BDX) EVP Sells $990,787.83 in Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Roland Goette sold 4,483 shares of the firm’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $221.01, for a total value of $990,787.83. Following the completion of the transaction, the executive vice president now directly owns 24,345 shares in the company, valued at approximately $5,380,488.45. This represents a 15.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Roland Goette also recently made the following trade(s):

• On Monday, December 9th, Roland Goette sold 638 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $219.03, for a total value of $139,741.14.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock traded down $1.66 during trading on Tuesday, reaching $221.35. 1,804,078 shares of the stock traded hands, compared to its average volume of 1,443,634. The company has a market capitalization of $64.00 billion, a price-to-earnings ratio of 37.28, a P/E/G ratio of 1.64 and a beta of 0.41. The business has a fifty day simple moving average of $232.24 and a two-hundred day simple moving average of $233.54. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $249.89.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping the consensus estimate of $3.77 by $0.04. The company had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The firm’s revenue was up 6.9% on a year-over-year basis. During the same quarter last year, the business posted $3.42 earnings per share. Sell-side analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be given a $1.04 dividend. The ex-dividend date is Monday, December 9th. This represents a $4.16 annualized dividend and a yield of 1.88%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 63.97%.

Institutional Trading of Becton, Dickinson and Company

Several institutional investors have recently added to or reduced their stakes in BDX. Dynamic Advisor Solutions LLC lifted its stake in Becton, Dickinson and Company by 24.1% in the second quarter. Dynamic Advisor Solutions LLC now owns 2,069 shares of the medical instruments supplier’s stock worth $483,000 after purchasing an additional 402 shares during the last quarter. Sequoia Financial Advisors LLC raised its stake in shares of Becton, Dickinson and Company by 9.9% during the second quarter. Sequoia Financial Advisors LLC now owns 4,935 shares of the medical instruments supplier’s stock valued at $1,153,000 after acquiring an additional 446 shares in the last quarter. Burke & Herbert Bank & Trust Co. bought a new stake in shares of Becton, Dickinson and Company during the second quarter valued at approximately $237,000. Diversified Trust Co bought a new stake in shares of Becton, Dickinson and Company during the second quarter valued at approximately $284,000. Finally, NorthCrest Asset Manangement LLC raised its stake in shares of Becton, Dickinson and Company by 1.8% during the second quarter. NorthCrest Asset Manangement LLC now owns 7,740 shares of the medical instruments supplier’s stock valued at $1,809,000 after acquiring an additional 139 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price target for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Evercore ISI raised their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $283.50.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.